Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

APC 8015

Known as: APC-8015, APC8015, APC8015 Vaccine 
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
The management of advanced prostate cancer, specifically metastatic castrate-resistant prostate cancer (mCRPC), remains a… Expand
Is this relevant?
Review
2011
Review
2011
As the most common malignancy among North American males, prostate cancer causes more than 30,000 deaths each year. After local… Expand
Is this relevant?
Review
2007
Review
2007
Prostate cancer is a major cause of mortality in men in the Western world. Although treatment of early stage prostate cancer with… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE Sipuleucel-T (APC8015) is an investigational immunotherapy product designed to stimulate T-cell immunity against… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND APC8015 (sipuleucel-T) is a cellular prostate cancer vaccine containing autologous antigen-presenting cells (APC… Expand
Is this relevant?
2005
2005
BACKGROUND Antigen-presenting cells 8015 (APC8015; Provenge) is an immunotherapeutic product designed to initiate a T-cell… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Prostate cancer is the most commonly diagnosed malignancy in American men, yet treatment of its metastatic androgen… Expand
Is this relevant?
Review
2002
Review
2002
  • Brian I. Rini
  • Current opinion in molecular therapeutics
  • 2002
  • Corpus ID: 43594022
Dendreon (formerly Activated Cell Therapy), in association with the Mayo Clinic, is developing the dendritic cell therapy APC… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
We attempted to induce therapeutic immunity against prostate-derived tissues in patients suffering from progressive hormone… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?